Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-22

Clinical Trial Update: A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating tocilizumab for idiopathic retroperitoneal fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tocilizumab (tocilizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Idiopathic Retroperitoneal Fibrosis | Phase 4 | Status: UNKNOWN